Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Robarts Research Institute Pfizer |
---|---|
Information provided by: | Robarts Research Institute |
ClinicalTrials.gov Identifier: | NCT00637078 |
The objective of this study is to assess if the implementation of a treatment algorithm including initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination and subsequently a low dose DHP-CCB/statin combination will improve the management of hypertension/hypercholesterolemia compared to guidelines-base management at family practices.
Condition | Intervention | Phase |
---|---|---|
Hypertension Hypercholesterolemia |
Other: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Evaluation of a Primary Treatment Algorithm Using Combination Therapy for the Management of Patients With Hypertension and Hypercholesterolemia |
Estimated Enrollment: | 2500 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Drug: Fix dose combination therapy
|
Other: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide
initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
|
2: No Intervention
Guidelines based management
|
Utilization of fixed dose combination therapy has been advocated as an adherence-enhancing strategy and has been so recommended in the 2007 Canadian Hypertension Education Program (CHEP) recommendations. Further, in a previous study (STITCH) it was demonstrated that a simplified treatment algorithm utilizing initial therapy with a low dose fixed-dose combination therapy improved blood pressure control in hypertensive patients. However, the effectiveness of either a simplified treatment algorithm or the initial use of fixed dose combination therapies for 2 risk factors in hypertensive dyslipidemic patients has yet to be determined. Therefore, the current study is designed to determine whether utilization of a fixed dose combination hypertension/hypercholesterolemia therapy results in improved adherence, patient satisfaction as well as improved rates of reaching target LDL cholesterol and blood pressure.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Robarts Research Insititute | |
London, Ontario, Canada, N6A 5K8 |
Principal Investigator: | Ross Feldman, MD | Deputy Director |
Principal Investigator: | George Dresser, MD | Co prinicipal investigator |
Responsible Party: | Robarts Research Institute and London Health Sciences (Dr. Dresser) ( Ross Feldman, MD and George Dresser, MD ) |
Study ID Numbers: | RPO702 |
Study First Received: | March 3, 2008 |
Last Updated: | February 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00637078 History of Changes |
Health Authority: | Canada: Health Canada |
hypertension hypercholesterolemia family physicians fixed dose combination therapy cluster randomized controlled trial |
Hyperlipidemias Metabolic Diseases Hormone Antagonists Diuretics Hormones, Hormone Substitutes, and Hormone Antagonists Vascular Diseases Cardiovascular Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Hormones |
Spironolactone Amlodipine Aldosterone Antagonists Angiotensin-Converting Enzyme Inhibitors Hypercholesterolemia Metabolic Disorder Dyslipidemias Hypertension Lipid Metabolism Disorders |
Hyperlipidemias Metabolic Diseases Hormone Antagonists Diuretics Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Vascular Diseases Cardiovascular Agents Pharmacologic Actions |
Spironolactone Aldosterone Antagonists Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Hypercholesterolemia Dyslipidemias Hypertension Lipid Metabolism Disorders |